Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients

// Dawei Chen 1,2,* , Yan Zhang 2,3,* , Fang Shi 2,3 , Hui Zhu 2, 3 , Minghuan Li 2,3 , Kaijun Chen 4 , Li Kong 2,3 and Jinming Yu 2,3 1 Weifang Medical University, Weifang, China 2 Department of Radiation Oncology, Shandong Cancer Hospital affiliated to Shandong University, Jinan, China 3 Shandong Academy of Medical Sciences, Jinan, China 4 Department of Clinical Laboratory, Mengyin People’s Hospital, Linyi, China * These authors have contributed equally to this work Correspondence to: Li Kong, email: // Jinming Yu, email: // Keywords : bevacizumab, intrapericardial, malignant pericardial effusion, advanced cancer Received : January 14, 2016 Accepted : May 09, 2016 Published : May 17, 2016 Abstract We evaluated the safety and efficacy of intrapericardial bevacizumab (BEV) for treating symptomatic malignant pericardiac effusion (MPCE) in seven advanced cancer patients. All patients had previously undergone multiple lines of systemic therapy. Each patient received paracentesis and intrapericardial infusions of 100 or 200 mg of BEV every two weeks. Systemic treatments for primary tumors continued for all patients during BEV treatment. Of the seven patients, three achieved a complete response, two achieved a partial response, and two showed no response with regard to MPCE after BEV infusion. The median overall survival time was 168 days (range, 22-224 days). In six of the seven patients, effusion did not recur before death. Toxicity associated with BEV treatment was mild and manageable in all patients. This study provides preliminary evidence that intrapericardial BEV may be an effective and safe treatment for MPCE in patients with advanced cancers.